Airway smooth muscle NOX4 is upregulated and modulates ROS generation in COPD

Fay Hollins\textsuperscript{1†}, Amanda Sutcliffe\textsuperscript{1†}, Edith Gomez\textsuperscript{1}, Rachid Berair\textsuperscript{1}, Richard Russell\textsuperscript{1}, Cédric Szyndralewiez\textsuperscript{2}, Ruth Saunders\textsuperscript{1} and Christopher Brightling\textsuperscript{1*}

Abstract

The burden of oxidative stress is increased in chronic obstructive pulmonary disease (COPD). However, whether the intra-cellular mechanisms controlling the oxidant/anti-oxidant balance in structural airway cells such as airway smooth muscle in COPD is altered is unclear. We sought to determine whether the expression of the NADPH oxidase (NOX)-4 is increased in airway smooth muscle in COPD both in vivo and primary cells in vitro and its role in hydrogen peroxide-induced reactive oxygen species generation. We found that in vivo NOX4 expression was up-regulated in the airway smooth muscle bundle in COPD (\(n=9\)) and healthy controls with >20 pack year history (\(n=4\)) compared to control subjects without a significant smoking history (\(n=6\)). In vitro NOX4 expression was increased in airway smooth muscle cells from subjects with COPD (\(n=5\)) compared to asthma (\(n=7\)) and upregulated following TNF-\(\alpha\) stimulation. Hydrogen peroxide-induced reactive oxygen species generation by airway smooth muscle cells in COPD (\(n=5\)) was comparable to healthy controls (\(n=9\)) but lower than asthma (\(n=5\)); and was markedly attenuated by NOX4 inhibition. Our findings demonstrate that NOX4 expression is increased in vivo and in vitro in COPD and although we did not observe an intrinsic increase in oxidant-induced reactive oxygen species generation in COPD, it was reduced markedly by NOX4 inhibition supporting a potential therapeutic role for NOX4 in COPD.

Keywords: COPD, Oxidative stress, Reactive oxygen species, Airway smooth muscle, NOX4
control was measured in ASM bundles by thresholding using Cell^F software (Olympus, UK), where the thresholding levels set on Hue, Saturation and Intensity scales by an observer blinded to the subjects' clinical characteristics.

Pure ASM bundles were isolated from bronchoscopic samples and used at passages 2–6. Real-Time Reverse Transcription–Polymerase Chain Reaction was performed (SuperScript Vilo cDNA synthesis kit, Express SYBR GreenER qPCR Supermix Universal; Invitrogen). Relative quantification of NOX4 mRNA expression was done using the comparative 2^ΔΔCt method and expressed as fold change as previously described [12], with amplification of 18S RNA as the internal normaliser gene (18 s forward primer: h18SRNA.891 F:GTTGGTTTTCGGAACCTGG, 18 s reverse primer: h18SRNA.1090R:GCA TCGTTTAGGTCCGGAAC; NOX4 forward primer: hNox4.598 F:TGGCTGCCCATCTGGTGAATG, and NOX4 reverse primer: hNox4.478R:CAAGCAGCCTC CTGAAACATGC. ASM was stained with a NOX4 monoclonal Alexa Fluor 488 conjugated antibody (Abcam) with or without prior incubations with 50 ng/ml TNFa for 24 h. Intracellular reactive oxygen species (ROS) was assessed by incubating the ASM with 10 mM 5-(and-6-)chloromethyl-29,79-dichlorodihydrofluorescein diacetate (DCFDA) [8] in the presence or absence of the NOX4 inhibitor 10 μM (GKT137831 gift from Genkyotex).

Statistical analysis was performed using PRISM Version 6 (GraphPad, La Jolla, CA). Parametric data were presented as mean (SEM) and nonparametric data as median (interquartile range). Analysis between groups was by t tests or Mann–Whitney tests and across groups by ANOVA or repeated measures ANOVA for paired data with appropriate post hoc pairwise comparisons. Correlation by Spearman rank test. P < 0.05 was considered significant.

Representative photomicrographs illustrating NOX4 expression in the ASM are as shown (Fig. 1a). NOX4 ASM expression was increased in the subjects with COPD and the control subjects with a >20 pack year smoking history compared to the control subjects with ≤20 pack year history (21.5 ± 2.9 % and 25.7 ± 3.3 versus 5.9 ± 1.7 % respectively; P < 0.001; Fig. 1b). The intensity of NOX4 expression was positively correlated with smoking history in the group as a whole (r = 0.48; P = 0.037) and healthy controls (r = 0.72; P = 0.019), but not for the subjects with COPD (r = 0.11; P = 0.785; Fig. 1c).

NOX4 mRNA expression by primary cultured ASM from COPD subjects was not significantly different to either healthy controls (P = 0.174; Fig. 1d), nor our previously published NOX4 mRNA expression by ASM from asthmatic subjects (data not shown) [8]. We have reported that NOX4 protein expression as measured by flow cytometry was elevated in ASM from asthmatic compared to healthy subjects [8]. Here we show that the percentage of cells expressing NOX4 is significantly elevated in ASM from COPD versus asthmatic subjects (40% of the asthma subjects were included in our previous report [8]) (91 ± 1 % versus 72 ± 7 % respectively; P = 0.046, Fig. 1e), although there was no difference in the geometric mean fluorescence intensity. Following treatment with 50 ng/ml TNFa for 24 h the geometric mean fluorescence intensity of NOX4 expression was significantly elevated in COPD (mean fold difference [95 % CI] 1.32 [1.22–1.43]; P < 0.001), but not asthmatic subjects (1.06-fold [0.93 to 1.21]; P = 0.29) (Fig. 1f).

ASM-derived from subjects with asthma, COPD and healthy controls were stimulated with hydrogen peroxide (10 mM). This concentration was chosen as a submaximal stimulus to promote ROS production without affecting cell viability. Following hydrogen peroxide exposure, there was an increase in the production of ROS by ASM from subjects with COPD, asthma and healthy controls (Fig. 1g). This increase was significantly greater in those with asthma compared to healthy controls and COPD, but was not different between COPD and health (Fig. 1g). This oxidant-induced ROS production was abrogated by the addition of NOX4 inhibitor (mean difference [95 % CI] -496.3 [–647.7 to –344.9]; P = 0.0001; Fig. 1h).

We show for the first time that in vivo NOX4 expression is up-regulated in ASM from COPD subjects and smokers with a >20 pack year history compared to smokers with a ≤20 pack year smoking history, and positively correlates to pack year history. We show that the percentage of NOX4 protein expression is significantly increased in primary ASM cells from COPD subjects compared to asthmatic subjects and that the intensity of expression is increased in COPD ASM following activation by TNFa. Oxidant-induced ROS generation in ASM from COPD subjects was similar to healthy control ASM and less than ASM-derived from asthmatic subjects. This oxidant-induced ASM ROS generation was completely abrogated by NOX4 inhibition in those subjects with or without COPD.

Oxidant/antioxidant imbalance is an important pathogenic factor in COPD [9]. This imbalance may be a consequence of environmental insults, the inflammatory milieu in COPD or due to abnormalities in the dynamic and complex processes involved in the generation and detoxification of ROS. Few studies have addressed the role of NOX4. Milara et al. showed that NOX4 expression and ROS generation are enhanced following exposure of human bronchial epithelial cells to cigarette smoke extract [13]. We have shown for the first time that in vivo NOX4 protein expression in ASM is elevated in COPD and controls with significant smoking histories. In addition we found that NOX4 protein
Fig. 1 (See legend on next page.)
expression in ASM cells from COPD subjects was further elevated compared to ASM from asthmatic subjects, and that the intensity of this expression in ASM from COPD subjects was enhanced in the presence of TNFα, which is increased in COPD [11].

Basal levels of ROS generation were not different between ASM from healthy control, asthmatic and COPD subjects. In contrast to the increase seen in asthma, the amount of ROS generated following stimulation with hydrogen peroxide using the DCFDA assay was similar in ASM from COPD subjects and healthy controls. Possible explanations for this apparent anomaly include differential NOX4 activity or activation/suppression of NOX4 independent pathways in the ASM derived from COPD subjects versus healthy controls. NOX4 plays an important role in the overall oxidative burden of the ASM, as demonstrated by our data showing that H2O2 stimulated ROS production in ASM can be completely abrogated with a NOX4 inhibitor. However the magnitude of this role in COPD needs to be further studied in vivo. It has previously been shown that NOX4 up-regulation and consequent ROS generation promote TGF-β1-induced proliferation and hypertrophy of ASM [14]. Whether up-regulation of NOX4 expression, and the oxidative burden in COPD in vivo contribute to ASM dysfunction in COPD subjects remains to be determined.

Thus, we provide evidence for up-regulation of NOX4 expression in vivo and in vitro in the ASM from COPD subjects and complete abrogation of oxidant-induced ROS generation by NOX4 inhibition. The development of NOX4 small molecule inhibitors in clinical trials for other disease indications (NCT02010242) means that the role of NOX4 in COPD could be tested in the clinic in the near future.

Acknowledgements
The authors thank Genkyotex, Switzerland for donating compound GKT137831. The authors also thank all the clinical staff for helping with collecting samples and patient details, and the patients who participated in this study. In addition, we would like to thank Latifa Chachi, Aarti Palmer, Natasha Johnson, Michelle Powell and Adelina Gavrila for their technical assistance.

Funding
The authors thank the following funding bodies: Wellcome Trust Senior Clinical Fellowship (CB), Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through FP7 EU grant), and Leicester NIHR Respiratory Biomedical Unit. This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Availability of data and materials
The dataset supporting the conclusions of this article is included within the article.

Authors’ contributions
FH conducted the experiments, analysed the data, participated in the experimental design and wrote the manuscript. AS conducted the experiments and analysed the data. EG conducted the experiments and analysed the data. RB analysed the data. RR analysed the data. CS conceived the study and participated in the experimental design. RS conducted the experiments, analysed the data, participated in the experimental design and wrote the manuscript. CB conceived the study, participated in the experimental design and data analysis, and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests
CB has received grants and consultancy fees paid to his Institution GSK, AZ, Bi, Novartis, Vectura and Chiesi. CS is employed by Genkyotex and received some shares of the company. All other authors have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the Leicestershire Ethics Committee and all patients gave their written informed consent.

Author details
1Institute for Lung Health, Department of Infection, Immunity & Inflammation, Glenfield Hospital, University of Leicester, Leicester LE3 9QP, UK. 2Genkyotex, Geneva, Switzerland.

Received: 14 May 2016 Accepted: 9 July 2016
Published online: 19 July 2016

Abbreviations
ASM, airway smooth muscle; COPD, chronic obstructive pulmonary disease; DCFDA, 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate; NOX4, nicotinamide adenine dinucleotide phosphate oxidase type 4; ROS, reactive oxygen species; TGFβ, transforming growth factor β; TNFα, tumour necrosis factor α
References
1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). (http://www.goldcopd.org/). Date last updated: December 2015. Date last Accessed: 24 Mar 2016.
2. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. CG101, (http://www.nice.org.uk/CG101). Date last updated: 23rd June 2010. Data last Accessed 18 Mar 2016.
3. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1090–5.
4. Fischer BM, Voynow JA, Ghio AJ. COPD: balancing oxidants and antioxidants. Int J Chron Obstruct Pulmon Dis. 2015;10:261–76.
5. Hamid Q, Cosio M, Lim S. Inflammation and remodeling in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2004;114:1479–81.
6. Pini L, Pinelli V, Modina D, Bezza M, Tiberio L, Tantucci C. Central airways remodeling in COPD patients. Int J Chron Obstruct Pulmon Dis. 2014;9:27–32.
7. Riess A, Wiggs B, Verburgt L, Wright JL, Hogg JC, Paré PD. Morphologic determinants of airway responsiveness in chronic smokers. Am J Respir Crit Care Med. 1996;154:1444–9.
8. Sutcliffe A, Hollins F, Gomez E, Saunders R, Dce C, Cooke M, Challiss RA, Brightling CE. Increased nicotinamide adenine dinucleotide phosphate oxidase 4 expression mediates intrinsic airway smooth muscle hypercontractility in asthma. Am J Respir Crit Care Med. 2012;185:267–74.
9. Kilkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther. 2006;111:476–94.
10. Vignola AM, Chanez P, Chihara G, Merendino A, Pace E, Rizzo A, la Rocca AM, Bellia V, Bonsignore C, Bouquet J. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med. 1997;156:591–9.
11. Chiang CH, Chuang CH, Liu SL. Transforming growth factor-beta1 and tumor necrosis factor-a are associated with clinical severity and airflow limitation of COPD in an additive manner. Lung. 2014;192:95–102.
12. Manea A, Tanase Li, Raicu M, Simionescu M. JAK/STAT signalling pathway regulates Nox1 and Nox4-based NADPH oxidase in human aortic smooth muscle cells. Atheroscler Thromb Vasc Biol. 2010;30:105–12.
13. Milara J, Peiró T, Serrano A, Gijarro R, Zaragoza C, Tenor H, Cortijo J. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD. Pulm Pharmacol Ther. 2014;28:138–48.
14. Sturrock A, Huecksteadt TP, Norman K, Sanders K, Murphy TM, Chitano P, Wilson K, Hoidal JR, Kennedy TP. Novel mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1543–55.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit